Matter Bioworks: Pioneering Longevity Through Genomic Integrity

Matter Bioworks is a longevity company committed to preserving genomic integrity. Drawing inspiration from the information theory of aging, we posit that age-related diseases—and possibly aging itself—result from the accumulated loss of DNA integrity due to damage.

As we age, our genomes accrue damage from both external and internal sources at a roughly linear rate. While cells possess powerful DNA repair mechanisms, these systems are not infallible. Errors can be missed, leading to mutations, structural variations, epigenetic drift, and other forms of information loss. This accumulation triggers a cascade of problems that culminate in age-related diseases.

Nature's Blueprint for Longevity

Research into extreme longevity across various species reveals a consistent pattern: longer-lived animals exhibit superior genome stability and DNA repair capabilities compared to their shorter-lived counterparts. This phenomenon is observed in species such as naked mole rats, rockfish, bowhead whales, Greenland sharks, and even supercentenarian humans.

At Matter, we aim to harness these naturally occurring DNA stability variants and deliver them to human cells to dramatically enhance cellular longevity. We are addressing four critical stages in the decay of biological information:

1. Read: Employ ultra-high-resolution error-corrected sequencing (ecNGS) to precisely understand genomic changes.
2. Repair: Utilize pro-longevity gene variants to bolster DNA repair mechanisms and maintain genomic integrity.
3. Replace: Substitute genes that have become excessively corrupted and pathological, including oncogenes and genes involved in inherited progeroid disorders.
4. Remove: Safely eliminate cells that have accumulated irreversible damage, such as tumor cells and senescent cells.

Our Pipeline

• Revenue-Generating ecNGS Sequencing: Providing cutting-edge sequencing services to understand genomic alterations with unprecedented accuracy.
• Clinical-Stage Solid Tumor Program: Entering Phase 1 clinical trials to target and remove cancerous cells.
• Pre-Clinical DNA Editing Program: Developing therapies to repair or replace damaged genes associated with aging and disease.

Our Team

Our co-founders are leaders in the fields of genetics, aging, and biotechnology:

• Chris Bradley, MS: With 16 years of startup experience and a successful exit.
• Sam Sharifi, PhD: An expert in aging science.
• George Church, PhD: Harvard University.
• Jan Vijg, PhD: Albert Einstein College of Medicine.